The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Abacavir/Lamivudine Mylan Pharma 600 mg/300 mg Film-coated Tablets

McDermott Laboratories Ltd., T/A Gerard LaboratoriesPA0577/216/001

Main Information

Trade NameAbacavir/Lamivudine Mylan Pharma 600 mg/300 mg Film-coated Tablets
Active SubstancesAbacavir sulfate
Dosage FormFilm-coated tablet
Licence HolderMcDermott Laboratories Ltd., T/A Gerard Laboratories
Licence NumberPA0577/216/001

Group Information

ATC CodeJ05AR Antivirals for treatment of HIV infections, combinations
J05AR02 lamivudine and abacavir


License statusAuthorised
Licence Issued10/11/2017
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2)
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Educational Materials - Patient

« Back